

# Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

NCT06455748

---

Status	RECRUITING
Phase	Not Applicable
Sponsor	Yongyong MA
Enrollment	20 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Age: 18-80 years old, diagnosed with primary amyloidosis of AL tissue;
- ECOG PS score 0-2 points;
- Measurable disease: The difference between affected and unaffected FLC is  $>20$  mg/L, and the serum immunoglobulin kappa  $\gg$  FLC ratio is abnormal;
- Having sufficient organ and bone marrow function, defined as follows:
- Blood routine: Absolute neutrophil count  $\geq 1.0 \times 10^9/L$ , platelet count  $\geq 50 \times 10^9/L$ ;
- ... and 4 more (see full listing online)

### Exclusion (18)

- Non AL amyloidosis;
- Known to be allergic, hypersensitive or intolerant to monoclonal antibodies or human derived proteins, daretozumab or its excipients, or known to be allergic to mammalian derivatives;
- Female patients who have tested positive for lactation or serum pregnancy test during the screening period;
- Received ASCT or had graft-versus-host disease in the past 12 months;
- Suffering from moderate or severe persistent asthma within 2 years prior to enrollment, or having uncontrolled asthma at the time of enrollment;
- ... and 13 more (see full listing online)

## Locations (1 total)

---

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

---

<https://clinicaltrials.gov/study/NCT06455748>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).